News
![Boehringer Ingelheim, Biberach, Germany, February 2007](https://pharmaphorum.com/wp-content/uploads/2016/05/BI-sign.jpg)
Boehringer takes alteplase to phase 3 for COVID, but drops a...
Boehringer Ingelheim's latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme